Causes of Cancer Cell Resistance to Chemotherapy Drugs Discovered
Technion-Israel Institute of Technology researchers, under the direction of Professor Yehuda Assaraf, discovered two mechanisms developed by cancer cells via mutation to become resistant to various chemotherapy drugs and how to prevent it; a breaktrhrough which could lead to new approaches for fighting drug-resistant tumors.
The findings were published in two articles in the scientific journal Cancer Research.
In the first research Yehuda’s team discovered that during chemotherapy, a mutation takes place in the protein ABCG2. This mutation gives ABCG2 the ability to transport a wide variety of anticancer drugs from the anti-folate family outside of the malignant cell. (Anti-folates are used in treating various cancerous growths such as breast cancer, colon cancer, leukemia, and cancer of the membrane that envelops the lung.) As a result, these malignant cells escape the effects of the drugs and become 6000 times more resistant to anticancer drugs, leading to a rapid spread of the disease.
“The mutation is an event in which a single amino acid changes in the structure of the ABCG2 protein, which then acts as a pump to transfer out the various anticancer drugs,” explains Assaraf.
During their study, the researchers succeeded in delaying the mutation from occurring. This enabled the anti-cancer drugs to effectively do their intended work.
This discovery could have important ramifications for cancer treatments. The researchers are already working on developing drugs to stop the ABCG2 mutation from occurring.
In the second project, published in Cancer Research on December 1, 2005, Assaraf and doctoral student Ilan Ifergan discovered another resistance mechanism connected to the ABCG2 carrier. They found that cancer cells create “waste baskets” into which anti-cancer drugs are deposited.
The pair found that cells neighboring breast cancers create among themselves balloon-like vesicles that serve as self-emptying wastebaskets into which the mutated ABCG2 proteins move the anti-cancer drugs.
“The mutated ABCG2 protein is found in large quantities in the extra cellular membrane of these vesicles located among the neighboring cancer cells. It ‘cleans’ the cancer cells of chemotherapy drugs such as mitoxantrone and collects them in these vesicles, which enlarge and inflate until the drug concentration is a thousand times greater than in the surrounding cell culture,” explains Assaraf. “This is a completely new resistance mechanism practiced by breast cancer cells to fight the lethal activities of anticancer drugs.”
The researchers were again able to demonstrate that delaying the mutation left the anticancer drugs inside the malignant cells, making it possible to very effectively kill the cancer cells located there.
Source: http://www.ats.org/
You may also like to read
- Chemotherapy Can Be More Effective on Lung Cancer by Overcoming Drug Resistance
- Nicotine Gum Can Protect Cancer Cells from Chemotherapy Drugs
- Chemo Gene May Helps Cancer Survive
- Reovirus Used To Eliminate Cancer Cells From Autologous Stem Cell Transplants
- Newly Found Gene Can Change The Way Of Treating Cancer
